Previous 10 | Next 10 |
Hexindai (NASDAQ: HX ) -41% . More news on: Hexindai Inc., Usio, Inc., Biofrontera AG, Stocks on the move, , Read more ...
Acer Therapeutics (NASDAQ: ACER ) : Q2 GAAP EPS of -$0.56 misses by $0.18 . More news on: Acer Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Advanced expanded pipeline of clinical stage product candidates, including emetine for COVID-19 and ACER-001 for Urea Cycle Disorders NEWTON, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development...
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. "For the first time in ten years, we were unable to host our mid-year conference, which ...
Insider buying decreased last week with insiders purchasing $88.83 million of stock compared to $99.17 million in the week prior. Selling also decreased with insiders selling $1 billion of stock last week compared to $1.29 billion in the week prior. Sell/Buy Ratio: The insider Sell/Buy rat...
Thinly traded nano cap Acer Therapeutics (NASDAQ: ACER ) jumps 20% premarket on modestly higher volume in reaction to results from a food effect study in 36 healthy volunteers that showed administration with ACER-001 in a fasted state increased systemic exposure of phenylbutyra...
Document Security Systems (NYSEMKT: DSS ) +69% after its target acquisition Company, Impact Biomedical reports positive results of equivir and linebacker for treatment of COVID-19. More news on: Document Security Systems, Inc., Infinity Pharmaceuticals, Inc., Dolphin Entertainment...
Model suggests ACER-001, Acer’s taste-masked, immediate release formulation of sodium phenylbutyrate, may offer improved disease management in patients with Urea Cycle Disorders compared to current treatments Anticipate submitting ACER-001 NDA in H1 2021 assuming successful com...
Investment Thesis The coming weeks could unveil two new FDA approvals for Ultragenyx Pharmaceutical Inc. ( RARE ), boosting its efforts to sustain the growth momentum. Expecting the Phase 3 trial starts as early as this year, two more candidates are undergoing mid-stage studies with their ...
Acer Therapeutics Inc. (NASDAQ: ACER) is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, according to the company’s website (see here: www.ac...
News, Short Squeeze, Breakout and More Instantly...
Acer Therapeutics Inc. Company Name:
ACER Stock Symbol:
NASDAQ Market:
Acer Therapeutics Inc. Website:
AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Acer Therapeutics Inc. (ACER) is expected to report $-0.13 for Q3 2023